1. Home
  2. ATHA vs NAII Comparison

ATHA vs NAII Comparison

Compare ATHA & NAII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATHA
  • NAII
  • Stock Information
  • Founded
  • ATHA 2011
  • NAII 1980
  • Country
  • ATHA United States
  • NAII United States
  • Employees
  • ATHA N/A
  • NAII N/A
  • Industry
  • ATHA Medicinal Chemicals and Botanical Products
  • NAII Medicinal Chemicals and Botanical Products
  • Sector
  • ATHA Health Care
  • NAII Health Care
  • Exchange
  • ATHA Nasdaq
  • NAII Nasdaq
  • Market Cap
  • ATHA 21.0M
  • NAII 18.6M
  • IPO Year
  • ATHA 2020
  • NAII 1987
  • Fundamental
  • Price
  • ATHA $0.26
  • NAII $3.24
  • Analyst Decision
  • ATHA Buy
  • NAII
  • Analyst Count
  • ATHA 4
  • NAII 0
  • Target Price
  • ATHA $11.25
  • NAII N/A
  • AVG Volume (30 Days)
  • ATHA 204.2K
  • NAII 24.0K
  • Earning Date
  • ATHA 05-14-2025
  • NAII 05-13-2025
  • Dividend Yield
  • ATHA N/A
  • NAII N/A
  • EPS Growth
  • ATHA N/A
  • NAII N/A
  • EPS
  • ATHA N/A
  • NAII N/A
  • Revenue
  • ATHA N/A
  • NAII $121,853,000.00
  • Revenue This Year
  • ATHA N/A
  • NAII N/A
  • Revenue Next Year
  • ATHA N/A
  • NAII N/A
  • P/E Ratio
  • ATHA N/A
  • NAII N/A
  • Revenue Growth
  • ATHA N/A
  • NAII N/A
  • 52 Week Low
  • ATHA $0.22
  • NAII $2.57
  • 52 Week High
  • ATHA $3.67
  • NAII $7.26
  • Technical
  • Relative Strength Index (RSI)
  • ATHA 42.81
  • NAII 55.09
  • Support Level
  • ATHA $0.23
  • NAII $2.69
  • Resistance Level
  • ATHA $0.27
  • NAII $3.37
  • Average True Range (ATR)
  • ATHA 0.03
  • NAII 0.28
  • MACD
  • ATHA 0.00
  • NAII 0.06
  • Stochastic Oscillator
  • ATHA 27.53
  • NAII 70.24

About ATHA Athira Pharma Inc.

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.

About NAII Natural Alternatives International Inc.

Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segment. The company derives the majority of revenue from Private-Label Contract Manufacturing which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.

Share on Social Networks: